|
|
|
|
| Join editor Jeff Buguliskis on June 4, 2026, at 11 a.m. ET for Outsourced Pharma Live: Beyond Data Packages: Derisking Tech Transfer To CDMOs. Industry experts will explore how sponsors can better prepare for successful tech transfers by addressing common challenges including incomplete data packages, equipment differences, method variability, global standards, and CMC alignment. Learn strategies using smarter documentation, DOE, and in silico modeling to improve right-first-time transfer success. Register now |
|
|
|
| Unlocking Durable Allogeneic Cell Therapy | White Paper | Applied StemCell | Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up. | |
|
|
Advising The Biotech C-Suite To Reconsider Quality | By Louis Garguilo, chief editor, Outsourced Pharma | “I assist C-suite executives to transfer quality from a painful cost center to a competitive asset." It's the type of bold statement that draws one's attention. Chief Editor Louis Garguilo asked David Grote on what his assertion means materially – and how that’s applied to working with CDMOs. Here's their discussion that focuses on a transformation that moves executives from regarding quality as ‘overhead’ to recognizing quality as “an operational element for business advantage.” |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| PAT Monitoring And Control Roadmap | E-Book | BioPhorum | Implement PAT effectively with a roadmap that covers techniques, validation, data integrity, and lifecycle strategies to help teams improve quality, control, and productivity. |
|
|
| The Continuation Of A Journey | Article | Andelyn Biosciences | See how one family managed to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis. |
|
|
|
|
|
|
|
|
|
| Outsourced Pharma Capabilities Update - Cell Therapy | Join us on June 16th for a virtual event on cell therapy manufacturing and CDMO selection. Experts will discuss how early development decisions affect scalability, GMP manufacturing, tech transfer, supply chains, and commercial readiness. The session explores strategies to reduce downstream risks like inconsistent quality and operational delays. Intended for CMC, manufacturing, quality, regulatory, supply chain, and procurement professionals evaluating cell therapy outsourcing partners. Click here to learn more. |
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
